Andean highlanders adapt to thin air through epigenetic gene tuning, revealing a flexible, long-term path to altitude survival.

A placebo-controlled trial has shown that the oral AKT inhibitor engasertib could reduce the frequency and duration of ...

Ipatasertib showed significant activity in patients with AKT1E17K mutations, with a 24.1% objective response rate and a median response duration of 10.1 months. The trial's 6-month progression-free ...

DNA sequencing technology makes it possible to explore the genome to learn how humans adapted to live in a wide range of ...